Microvesicles as a biomarker for tumor progression versus treatment effect in radiation/temozolomide-treated glioblastoma patients

Translational Oncology

Volumn 7, Issue 6, 2014, Pages 752-758

  Koch, Cameron J ^a   Lustig, Robert A ^a   Yang, Xiang Yang ^a   Jenkins, Walter T ^a   Wolf, Ronald L ^a   Martinez Lage, Maria ^b   Desai, Arati ^b   Williams, Dewight ^b   Evans, Sydney M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD CYTOLOGY; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CRYOELECTRON MICROSCOPY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROVESICLE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PLATELET MICROPARTICLE; PSEUDOPROGRESSION; RADIOGRAPHY; REAL TIME POLYMERASE CHAIN REACTION; STEREOTACTIC BIOPSY; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 84915763634     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.10.004     Document Type: Article

References (29)

1. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, and Pizzolato G, et al (2002). Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20, 1375–1382.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, and Belanger K, et al (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10, 459–466.
3. Kruser T, Mehta M, and Robins H (2013). Pseudoprogression after glioma therapy: a comprehensive review. Expert Rev Neurother 13, 389–403.
4. Stone HB, Brown JM, Phillips TL, and Sutherland RM (1993). Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat Res 136, 422–434.
5. Camussi G, Deregibus MC, Bruno S, Cantaluppi V, and Biancone L (2010). Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 78, 838–848.
6. Ohno S, Ishikawa A, and Kuroda M (2013). Roles of exosomes and microvesicles in disease pathogenesis. Adv Drug Deliv Rev 65, 398–401.
7. Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, and Gaspar LE, et al (2013). Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol 14, e396–e406.
8. Shao H, Chung J, Balaj L, Charest A, Bigner DD, Carter BS, Hochberg FH, Breakefield XO, Weissleder R, and Lee H (2012). Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med 18, 1835–1840.
9. Graner MW, Alzate O, Dechkovskaia AM, Keene JD, Sampson JH, Mitchell DA, and Bigner DD (2009). Proteomic and immunologic analyses of brain tumor exosomes. FASEB J 23, 1541–1557.
10. Shah AH, Snelling B, Bregy A, Patel PR, Tememe D, Bhatia R, Sklar E, and Komotar RJ (2013). Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality? J Neurooncol 112, 141–152.
11. Quant EC and Wen PY (2011). Response assessment in neuro-oncology. Curr Oncol Rep 13, 50–56.
12. Oborski MJ, Laymon CM, Lieberman FS, and Mountz JM (2013). Distinguishing pseudoprogression from progression in high-grade gliomas: a brief review of current clinical practice and demonstration of the potential value of 18F-FDG PET. Clin Nucl Med 38, 381–384.
13. Agarwal A, Kumar S, Narang J, Schultz L, Mikkelsen T, Wang S, Siddiqui S, Poptani H, and Jain R (2013). Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression. J Neurooncol 112, 413–420.
14. Pouleau HB, Sadeghi N, Baleriaux D, Melot C, De Witte O, and Lefranc F (2012). High levels of cellular proliferation predict pseudoprogression in glioblastoma patients. Int J Oncol 40, 923–928.
15. Fabi A, Russillo M, Metro G, Vidiri A, Di Giovanni S, and Cognetti F (2009). Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice. Anticancer Res 29, 2607–2610.
16. MacArthur KM, Kao GD, Chandrasekaran S, Alonso-Basanta M, Chapman C, Lustig RA, Wileyto EP, Hahn SM, and Dorsey JF (2014). Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res 78, 2152–2159.
17. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry Jr WT, Carter BS, Krichevsky AM, and Breakefield XO (2008). Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10, 1470–1476.
18. Noerholm M, Balaj L, Limperg T, Salehi A, Zhu LD, Hochberg FH, Breakefield XO, Carter BS, and Skog J (2012). RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer 12, 22.
19. Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringner M, Morgelin M, Bourseau-Guilmain E, Bengzon J, and Belting M (2013). Exosomes reflect the hypoxic status of glioma cells and mediate hypoxiadependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A 110, 7312–7317.
20. Duijvesz D, Luider T, Bangma CH, and Jenster G (2011). Exosomes as biomarker treasure chests for prostate cancer. Eur Urol 59, 823–831.
21. Karolina DS, Tavintharan S, Armugam A, Sepramaniam S, Pek SL, Wong MT, Lim SC, Sum CF, and Jeyaseelan K (2012). Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab 97, E2271-2276.
22. Weilner S, Schraml E, Redl H, Grillari-Voglauer R, and Grillari J (2013). Secretion of microvesicular miRNAs in cellular and organismal aging. Exp Gerontol 48, 626–633.
23. Lee HS, Jeong J, and Lee KJ (2009). Characterization of vesicles secreted from insulinoma NIT-1 cells. J Proteome Res 8, 2851–2862.
24. Azevedo LC, Pedro MA, and Laurindo FR (2007). Circulating microparticles as therapeutic targets in cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2, 41–51.
25. Peinado H, Lavotshkin S, and Lyden D (2011). The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 21, 139–146.
26. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, and Ratajczak MZ (2005). Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 113, 752–760.
27. Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, and Ibrahim NK (2011). Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 17, 6888–6896.
28. He J, Yin Y, Luster TA, Watkins L, and Thorpe PE (2009). Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. Clin Cancer Res 15, 6871–6880.
29. Roseblade A, Luk F, Rawling T, Ung A, Grau GER, and Bebawy M (2014). Calpain inhibition: a new strategy to circumvent microparticle- mediated multidrug resistance in cancer. International Society of Extracellular Vesicles; 2014 [Rotterdam, Holland].